×
About 7,033 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  2,751 results

The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Child...
https://doi.org/10.1177/0003319720975635
Angiology Karapostolakis G, Vakaki M et. al.

Nov 27th, 2020 - Carotid intima-media thickness (cIMT) has been proposed as an early marker of subclinical atherosclerosis in high risk children. Children with heterozygous familial hypercholesterolemia have greater cIMT than matched healthy controls or their unaf...

Does Management of Lipid Lowering Differ Between Specialists and Primary Care: Insights...
https://doi.org/10.1111/ijcp.13861
International Journal of Clinical Practice; Langer A, Tan M et. al.

Nov 27th, 2020 - We studied whether significant differences in care gaps exist between specialists and PCPs. GOAL Canada enrolled patients with CVD or familial hypercholesterolemia (FH) and LDL-C > 2.0 mmol/L despite maximally tolerated statin therapy. During foll...

Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hyperchol...
https://doi.org/10.1016/j.atherosclerosis.2020.11.013
Atherosclerosis Reeskamp LF, Tromp TR et. al.

Nov 26th, 2020 - Statins suppress hepatic mRNA expression of ANGPTL3 encoding angiopoietin-like 3 in healthy subjects, but it is unknown if plasma ANGPTL3 concentrations are affected by statins prescribed to hypercholesterolemic patients in clinical practice. We t...

Mice lacking global Stap1 expression do not manifest hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685646
BMC Medical Genetics; Kanuri B, Fong V et. al.

Nov 24th, 2020 - Autosomal dominant familial hypercholesterolemia (ADH; MIM#143890) is one of the most common monogenic disorders characterized by elevated circulatory LDL cholesterol. Initial studies in humans with ADH identified a potential relationship with var...

Familial Hypercholesterolemia: A Reportable Disorder.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687847
Circulation Kullo IJ

Nov 23rd, 2020 - Familial Hypercholesterolemia: A Reportable Disorder.|2020|Kullo IJ,|

see more →

Guidelines  7 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  331 results see all →

Clinicaltrials.gov  3,485 results

The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Child...
https://doi.org/10.1177/0003319720975635
Angiology Karapostolakis G, Vakaki M et. al.

Nov 27th, 2020 - Carotid intima-media thickness (cIMT) has been proposed as an early marker of subclinical atherosclerosis in high risk children. Children with heterozygous familial hypercholesterolemia have greater cIMT than matched healthy controls or their unaf...

Does Management of Lipid Lowering Differ Between Specialists and Primary Care: Insights...
https://doi.org/10.1111/ijcp.13861
International Journal of Clinical Practice; Langer A, Tan M et. al.

Nov 27th, 2020 - We studied whether significant differences in care gaps exist between specialists and PCPs. GOAL Canada enrolled patients with CVD or familial hypercholesterolemia (FH) and LDL-C > 2.0 mmol/L despite maximally tolerated statin therapy. During foll...

Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hyperchol...
https://doi.org/10.1016/j.atherosclerosis.2020.11.013
Atherosclerosis Reeskamp LF, Tromp TR et. al.

Nov 26th, 2020 - Statins suppress hepatic mRNA expression of ANGPTL3 encoding angiopoietin-like 3 in healthy subjects, but it is unknown if plasma ANGPTL3 concentrations are affected by statins prescribed to hypercholesterolemic patients in clinical practice. We t...

Mice lacking global Stap1 expression do not manifest hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685646
BMC Medical Genetics; Kanuri B, Fong V et. al.

Nov 24th, 2020 - Autosomal dominant familial hypercholesterolemia (ADH; MIM#143890) is one of the most common monogenic disorders characterized by elevated circulatory LDL cholesterol. Initial studies in humans with ADH identified a potential relationship with var...

Familial Hypercholesterolemia: A Reportable Disorder.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687847
Circulation Kullo IJ

Nov 23rd, 2020 - Familial Hypercholesterolemia: A Reportable Disorder.|2020|Kullo IJ,|

see more →

News  455 results

Evinacumab, Novel Lipid-Lowerer, Extends Promise in Phase 2 Results
https://www.medscape.com/viewarticle/941043

Nov 15th, 2020 - Treatment with evinacumab, an investigational lipid-lowering drug with a novel mechanism of action, safely led to roughly a halving of LDL cholesterol levels in patients with treatment-refractory hypercholesterolemia in a multicenter, phase 2 stud...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.staging.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Inclisiran Effectively Lowers LDL Across High-risk Settings
https://www.staging.medscape.com/viewarticle/939172

Oct 14th, 2020 - Inclisiran (The Medicines Company) sustainably reduces low-density-lipoprotein (LDL) cholesterol levels across genotypes in heterozygous familial hypercholesterolemia (HeFH) and in the primary prevention setting in high-risk patients, suggest the ...

Inclisiran Effectively Lowers LDL Across High-risk Settings
https://www.medscape.com/viewarticle/939172

Oct 14th, 2020 - Inclisiran (The Medicines Company) sustainably reduces low-density-lipoprotein (LDL) cholesterol levels across genotypes in heterozygous familial hypercholesterolemia (HeFH) and in the primary prevention setting in high-risk patients, suggest the ...

see more →

Patient Education  4 results see all →